Skip to main content
Equibles

APLM · Apollomics Inc.

Track APLM — free

Use APLM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research APLM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$23.00 At close · Oct 5
Rebalance outlook locked
Market Cap
$70.31M
Shares
2.91M
Volume · Oct 1 1200 Avg daily vol (3M) 22.3K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$23.27 Open$23.00 Day$23.00–23.27 52W close$11.61–36.65 Avg vol 30d9K Short int6K · 0.2% float · 1.0d Short vol62% Last earningsDec 31, 2023 DataNov 2021–Oct 2026

Up next

Q4 2023 earnings call transcript
call held Dec 31, 2023

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+99.0%
Year over year · more shares
Price change (1Y)
+26.2%
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +24%
above
Price vs 50-day avg +4%
above
RSI (14) 49
neutral
MACD trend Negative
52-week position 47%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −15%
trailing
6-month return +59%
trailing
YTD return +24%
this year
Relative strength +46%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $22 › 200d $19 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +5 funds added
Insider flow Accumulating
Net +$8.3M over 90 days · 0% sells
Short interest Falling
0.19% of float · ▼ -23.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 3-yr range
Squeeze score 35
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 158%
annualized · 1-yr
Max drawdown −68%
past year
ATR 8.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+24% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
47% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $22 › 200d $19 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +5 funds added
Insider flow Accumulating
Net +$8.3M over 90 days · 0% sells
Short interest Falling
0.19% of float · ▼ -23.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $12 Now $23 · 47% Range high $37
vs 200-day avg +24% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
APLM
Apollomics Inc.
this stock
$70.31M +24.5% — — 0.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
17
% held
93.3%
Net QoQ
+285.4K sh
Top holder
HRT FINANCIAL LP
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
5.6K
Days to cover
1.0d
Change
-1.8K sh
View
Short Volume
Short vol %
62%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
279
Value
$7.0K
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
25.4%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$8.3M
Buyers / Sellers
3 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 12, 2026
This year
7
View
Proposed Sales
Value
$11.3M
Shares
9.5M
Filed
Nov 27, 2023
View
Exempt Offerings
Offering
$10.0M
Filed
Aug 19, 2026
View
Earnings & Events
Webcasts
Last webcast
Dec 31, 2023
View

Performance

5D 20D 120D MTD YTD
APLM -0.9% -14.9% +58.8% -6.8% +24.5%
SPY -0.4% -0.2% +12.4% +0.2% +12.0%
vs SPY -0.5% -14.8% +46.4% -6.9% +12.4%
Key facts CIK 1944885 CUSIP G0411D123 Visit website Investor relations